Emyria (ASX:EMD) Inventories, Finished Goods: A$0.00 Mil (As of Dec. 2025)


What is Emyria Inventories, Finished Goods?

Emyria ASX:EMD Inventories, Finished Goods is A$0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Emyria Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Emyria's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emyria Inventories, Finished Goods Chart

Emyria Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Inventories, Finished Goods
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Emyria Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Emyria Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of A$0.00 Mil mean?
Emyria (ASX:EMD) has a Inventories, Finished Goods of A$0.00 Mil as of Dec. 2025. Finished goods are inventory items that are complete and ready to be sold. View historical data on Emyria and its competitors.
Is Emyria's Inventories, Finished Goods too high?
Emyria's current Inventories, Finished Goods is A$0.00 Mil.
How does Emyria's Inventories, Finished Goods compare to VEEV and BTSG?
Emyria's Inventories, Finished Goods of A$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Healthcare Providers & Services company?
A good Inventories, Finished Goods depends on the Healthcare Providers & Services industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Emyria and its competitors. Emyria's current Inventories, Finished Goods is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emyria stock overvalued right now?
Based on GuruFocus' analysis, Emyria (ASX:EMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.04 — trading 36.7% above its estimated fair value. The current Inventories, Finished Goods is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Emyria (ASX:EMD), the current Inventories, Finished Goods is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emyria Business Description

Other Exchanges Q84:Germany
Address D2, 661 Newcastle Street, PO Box 1442, Leederville, WA, AUS, 6007
Emyria Ltd operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from consenting patients. It operates in one segment of research and development.